WebMay 4, 2024 · Brand name: Lartruvo Generic name: olaratumab Dosage form: Injection Company: Eli Lilly and Company Treatment for: Soft Tissue Sarcoma Lartruvo (olaratumab) is a platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody indicated in combination with doxorubicin for the treatment of patients with advanced soft tissue … WebMar 6, 2024 · Authorised This medicine is authorised for use in the European Union. Overview Calquence is a cancer medicine used to treat adults with chronic lymphocytic leukaemia (CLL), a blood cancer affecting B cells (a type of white blood cell). Calquence is used on its own (monotherapy) in patients with CLL who have had previous treatment.
History of Changes for Study: NCT04221477 - clinicaltrials.gov
WebAug 30, 2024 · FDA Approved: Yes (First approved November 13, 2013) Brand name: Imbruvica Generic name: ibrutinib Dosage form: Capsules, Tablets and Oral Suspension Company: AbbVie Inc. Treatment for: Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenström Macroglobulinemia, Graft-versus-host disease, Lymphoma WebTo report SUSPECTED ADVERSE REACTIONS, contact Kite at 1- 844-454-KITE (5483) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.... moscow theatre gas
Gazyva: Side Effects, Dosage & Uses - Drugs.com
WebGAZYVA is a CD20-directed cytolytic antibody indicated: • in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia. (1, … WebParticipants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80. Drug: Obinutuzumab Obinutuzumab will be administered by IV infusion at a dose of 1000 mg at Baseline and Weeks 2, 24, 26, 50 (group 2: placebo), and 52 and subsequently from Week 80 and every 6 months … WebMay 15, 2024 · NORTH CHICAGO, Ill., May 15, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved VENCLEXTA® (venetoclax) in combination with obinutuzumab (GAZYVA®) for previously untreated patients with … moscow theatre hostage crisis